Abstract:Abstract Background Immune checkpoint blockade (ICB) therapy targeting the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has achieved considerable success in treating a wide range of cancers. However, most patients are still resistant to ICB and lack of optimal biomarkers to predict response. Thus, uncovering the underlying cellular and molecular determinants of ICB resistance is needed to improve the efficacy of anti-PD-1/L1 therapy. Palmitoylation is mediated by a family of 23 S-acyltransferases, Asp-His‐His‐Cys type (ZDHHC) palmitoyltransferases, that precisely control various cancer-related protein functions, representing promising drug targets for cancer therapy. However, how specific ZDHHC palmitoyltransferases affect the tumour microenvironment (TME) and augment the therapeutic efficacy of ICB remains elusive. Methods Five syngeneic subcutaneous tumour models were used to demonstrate the anti-tumour activity of ZDHHC9 deficiency. Multispectral flow cytometry was used to characterize alterations in immune cell subsets. Two poorly immunogenic tumour models were used to evaluate the synergistic effect of ZDHHC9 deficiency and anti-PD-L1 therapy. A polymeric nanoparticle approach was developed for the in vivo delivery of ZDHHC9-siRNA to tumour tissues. The TGCA database was used to assess the expression pattern and immunological characteristics of ZDHHC9 in pan-cancers. Results We found that tumor cell-intrinsic “immuno-oncogene” Zinc Finger DHHC-Type Containing 9 (ZDHHC9) was overexpressed in various human cancers and associated with impaired anti-tumor immunity. In five syngeneic tumour models, the knockdown of ZDHHC9 expression in tumour cells was sufficient to suppress tumour progression and improve survival by reprogramming the immunosuppressive (‘cold’) to proinflammatory (‘hot’) TME. Furthermore, ZDHHC9 deficiency in tumour cells sensitized anti-PD-L1 immunotherapy in CD8+ T cells dependent manner. Lastly, we employed the ZDHHC9-siRNA nanoparticle system to efficiently silence ZDHHC9 in tumours whilst potentiating anti-PD-L1 immunotherapy in non-immunogenic tumours. Conclusion Tumour-intrinsic S-palmitoylation regulator ZDHHC9 tumour expression is a mechanism of inhibition of host anti-tumour immunity and reprogramming of immunosuppressive tumour microenvironment. Inactivating ZDHHC9 highlights an effective immunotherapeutic strategy and booster for anti-PD-L1 therapy.

BFAR Coordinates TGFβ Signaling to Modulate Th9-mediated Cancer Immunotherapy

BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses

Opposing Functions of Circadian Protein DBP and Atypical E2F Family E2F8 in Anti-Tumor Th9 Cell Differentiation

Age-related Decline in CD8+ Tissue Resident Memory T Cells Compromises Antitumor Immunity

Key Regulatory Elements of the TGFbeta-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across Cancer Types

Tgf-Beta 1 Promotes Colorectal Cancer Immune Escape By Elevating B7-H3 And B7-H4 Via The Mir-155/Mir-143 Axis

Overexpression of FBP1 Enhances Dendritic Cell Activation and Maturation by Inhibiting Glycolysis and Promoting the Secretion of IL33 in Lung Adenocarcinoma

Foxo1 and Foxp1 play opposing roles in regulating the differentiation and antitumor activity of TH9 cells programmed by IL-7

Pharmacological Inhibition and Genetic Knockdown of BCL9 Modulate the Cellular Landscape of Cancer-Associated Fibroblasts in the Tumor-Immune Microenvironment of Colorectal Cancer

Assessing TGF-β Prognostic Model Predictions for Chemotherapy Response and Oncogenic Role of FKBP1A in Liver Cancer

TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways

Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration

BATF2 Deficiency Promotes Progression in Human Colorectal Cancer Via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs.

Fructose-1,6-bisphosphatase Loss Modulates STAT3-dependent Expression of PD-L1 and Cancer Immunity.

Targeting ZDHHC9 enhances anti-PD-L1 immunotherapy efficacy by reprogramming the tumour microenvironment

Fas signaling-mediated T H 9 cell differentiation favors bowel inflammation and antitumor functions

BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer

Tissue Factor Overexpression in Triple-Negative Breast Cancer Promotes Immune Evasion by Impeding T-cell Infiltration and Effector Function.

Targeting ZDHHC9 potentiates anti-programmed death-ligand 1 immunotherapy of pancreatic cancer by modifying the tumor microenvironment

Th9 Cell Differentiation and Its Dual Effects in Tumor Development

Abstract 3978: B-cell activating factor (BAFF) enhances antitumor immunity